微生物失调对弥漫性大B细胞淋巴瘤免疫化疗疗效和安全性的影响
该研究收集189例初治新诊断弥漫性大B细胞淋巴瘤(DLBCL)患者的粪便样本,先行16S核糖体RNA基因测序(n=158),再对额外样本行全基因组鸟枪法测序(n=106),并与健康对照比较。DLBCL患者α多样性显著低于健康对照(P<.001),肠杆菌科丰度明显升高,且与发热性中性粒细胞减少及复发或进展相关(P<.001),肠杆菌科丰度越高无进展生存期越短(P=.007)。
要点
- DLBCL患者肠道α多样性显著低于健康对照(P<.001),微生物组成差异显著(P<.001)。
- 肠杆菌科在发热性中性粒细胞减少及复发或进展患者中显著富集(P<.001)。
- 肠杆菌科丰度越高无进展生存期越短(P=.007)。
核心结论
- DLBCL患者存在肠道微生物失调,肠杆菌科丰度与治疗结局及发热性中性粒细胞减少相关。
- 需进一步研究以阐明DLBCL肠道失调的来源和作用。
研究设计与样本
- 获取189例初治新诊断DLBCL患者的粪便样本,先行16S核糖体RNA基因测序(n=158),再对额外样本行全基因组鸟枪法测序(n=106),并与健康对照的微生物组数据比较。
主要发现
- DLBCL患者α多样性显著低于健康对照(P<.001),两组微生物组成差异显著(P<.001)。
- 患者中属于变形菌门的肠杆菌科丰度明显高于健康对照。
- 微生物功能分析显示与1型菌毛、生物膜形成及抗生素耐药相关的机会性致病关联。
- 肠杆菌科在发生发热性中性粒细胞减少的患者及发生复发或进展的患者中显著富集(P<.001)。
- 肠杆菌科丰度越高,无进展生存期越短(P=.007)。
关键数值与推荐
- α多样性在DLBCL患者中显著低于健康对照(P<.001)。
- 微生物组成在DLBCL患者与健康对照间差异显著(P<.001)。
- 肠杆菌科在发热性中性粒细胞减少患者及复发或进展患者中显著富集(P<.001)。
- 肠杆菌科丰度与更短的无进展生存期相关(P=.007)。
- 肠道微生物富含肠杆菌科的患者的细胞因子谱与白细胞介素6(P=.035)及干扰素γ(P=.045)水平显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究以阐明DLBCL肠道失调的来源和作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The gut microbiome influences cancer development and the efficacy and safety of chemotherapy but little is known about its effects on lymphoma. We obtained stool samples from treatment-naive, newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) (n = 189). We first performed 16S ribosomal RNA gene sequencing (n = 158) and then conducted whole-genome shotgun sequencing on additional samples (n = 106). We compared the microbiome data from these patients with data from healthy controls and assessed whether microbiome characteristics were associated with treatment outcomes. The alpha diversity was significantly lower in patients with DLBCL than in healthy controls (P < .001), and the microbial composition differed significantly between the groups (P < .001). The abundance of the Enterobacteriaceae family belonging to the Proteobacteria phylum was markedly higher in patients than in healthy controls. Functional analysis of the microbiome revealed an association with opportunistic pathogenesis through type 1 pili, biofilm formation, and antibiotics resistance. Enterobacteriaceae members were significantly enriched in patients who experienced febrile neutropenia and in those who experienced relapse or progression (P < .001). Interestingly, greater abundance of Enterobacteriaceae correlated with shorter progression-free survival (P = .007). The cytokine profiles of patients whose microbiome was enriched with Enterobacteriaceae were significantly associated with interleukin 6 (P = .035) and interferon gamma (P = .045) levels. In summary, patients with DLBCL exhibited gut microbial dysbiosis. The abundance of Enterobacteriaceae correlated with treatment outcomes and febrile neutropenia. Further study is required to elucidate the origin and role of gut dysbiosis in DLBCL.
引用
- Yoon SE, Kang W, Choi S, et al. The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma. Blood. 2023. PMID: 36724450. doi:10.1182/blood.2022018831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。